Comparative Pharmacology
Head-to-head clinical analysis: TIMOLOL versus TRANDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMOLOL versus TRANDATE.
TIMOLOL vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist (beta-blocker) that competively blocks beta-1 and beta-2 receptors, reducing heart rate, contractility, and cardiac output. In glaucoma, decreases intraocular pressure by reducing aqueous humor production.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
0.25-0.5 mg ophthalmic solution instilled twice daily; for oral: 10-20 mg twice daily.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
Clinical Note
moderateTimolol + Digoxin
"Timolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTimolol + Digitoxin
"Timolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateTimolol + Deslanoside
"Timolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateTimolol + Acetyldigitoxin
"Timolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal half-life: 4-5 hours (healthy adults); prolonged to 7-10 hours in renal impairment, 11-16 hours in hepatic impairment; clinical context: once-daily dosing for hypertension/glaucoma.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Renal: ~20% unchanged; hepatic metabolism accounts for ~80%, with metabolites excreted renally; minor biliary/fecal elimination (<5%).
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category A/B
Category C
Beta-Blocker
Beta-Blocker